During and after the procedure

During a Y90 procedure, also known as Yttrium-90 radioembolization, small radioactive beads (microspheres) are precisely delivered into the blood vessels that supply the liver tumor. This is done through a catheter, which is threaded into the hepatic artery under image guidance. The microspheres emit radiation locally, targeting the cancer cells while sparing the surrounding healthy tissue. This approach is effective for liver cancer, as it delivers a concentrated dose of radiation directly to the tumor.

Patients may experience some temporary symptoms, such as fatigue, mild abdominal discomfort, or nausea, which are generally well-tolerated. These effects typically subside within a few days. Serious side effects are uncommon but may include liver damage, infection, or ulcer formation in the stomach or intestines. It’s crucial for patients to discuss potential risks and benefits with their healthcare team before undergoing Y90 therapy. Overall, Y90 radioembolization is recognized for its efficacy and minimal invasiveness in the treatment of liver cancer.